Matthew Luchini
Stock Analyst at BMO Capital
(2.09)
# 2,901
Out of 5,179 analysts
35
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $7.22 | +315.51% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $1.05 | +17,995.24% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $16.97 | +306.60% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $37.00 | +181.08% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $2.41 | +2,182.16% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $10.10 | +900.00% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $737.71 | -14.60% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $510.68 | -75.72% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $134.25 | -52.33% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $32.52 | -56.95% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.10 | +5,344.65% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $28 → $14 | $10.13 | +38.20% | 1 | Aug 15, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $7.22
Upside: +315.51%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $1.05
Upside: +17,995.24%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $16.97
Upside: +306.60%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $37.00
Upside: +181.08%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $2.41
Upside: +2,182.16%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $10.10
Upside: +900.00%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $737.71
Upside: -14.60%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $510.68
Upside: -75.72%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $134.25
Upside: -52.33%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $32.52
Upside: -56.95%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.10
Upside: +5,344.65%
Aug 15, 2018
Maintains: Market Perform
Price Target: $28 → $14
Current: $10.13
Upside: +38.20%